UC Davis Comprehensive Cancer Center

Adaptive Announces Launch of Epic Integration for clonoSEQ®

Retrieved on: 
Wednesday, September 13, 2023

This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care.

Key Points: 
  • This integration will allow providers to order and review clonoSEQ minimal residual disease (MRD) testing results in Epic as they would for any test performed directly at the site of care.
  • clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT).
  • Integration with Epic EHR provides convenient access to clonoSEQ MRD results along with discrete data directly in patient records, enabling faster, more efficient decision-making for oncologists and equipping patients with real-time insights into their disease status.
  • Practices that wish to access clonoSEQ MRD testing directly via Epic should contact their Adaptive account representative or Adaptive’s Account Operations team at [email protected].

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

Retrieved on: 
Tuesday, September 12, 2023

Jonathan Riess, MD, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, presented encouraging early clinical and biomarker data supporting the combination treatment for patients with metastatic non-small cell lung cancer (NSCLC).

Key Points: 
  • Jonathan Riess, MD, lead investigator of the trial at the UC Davis Comprehensive Cancer Center, presented encouraging early clinical and biomarker data supporting the combination treatment for patients with metastatic non-small cell lung cancer (NSCLC).
  • Available biomarker results for some patients show vaccine-specific T cell expansion and complete clearance or considerable drop of ctDNA, indicating activity of the treatment after just 21 days.
  • As of the data cut-off in July 2023, 25 patients had been enrolled in the lung cohort of this basket trial.
  • Abstract Title: Ph 2 Trial of IO102-IO103 Vaccine Plus Pembrolizumab: Preliminary Results for the First-line Treatment of Lung Adenocarcinoma

The Caris Precision Oncology Alliance Welcomes UC Davis Comprehensive Cancer Center

Retrieved on: 
Thursday, August 17, 2023

IRVING, Texas, Aug. 17, 2023 /PRNewswire/ -- Caris Life Sciences® (Caris), the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that UC Davis Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA).

Key Points: 
  • IRVING, Texas, Aug. 17, 2023 /PRNewswire/ -- Caris Life Sciences ® (Caris), the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that UC Davis Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA).
  • UC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people.
  • "The participation of UC Davis Comprehensive Cancer Center in the collaborative network of the Caris Precision Oncology Alliance will provide our cancer patients with new opportunities for advanced molecular analysis of their tumors, leading to better informed treatment decisions tailored to each patient's specific cancer.
  • "We are excited to welcome the UC Davis Comprehensive Cancer Center into the growing Caris Precision Oncology Alliance network," said Chadi Nabhan , M.D., MBA, FACP, Chairman of the POA.

Crush Challenge Returns for 9th Year on August 26 to the Napa Valley

Retrieved on: 
Thursday, July 27, 2023

NAPA, Calif., July 27, 2023 /PRNewswire-PRWeb/ -- ZD Wines and the deLeuze Family Charitable Foundation are excited to announce that Crush Challenge, the ultimate food, wine, and cycling lifestyle event in Napa Valley, returns this year on Saturday, August 26, 2023.

Key Points: 
  • Napa Valley Event Offers Cyclists, Foodies, and Wine Lovers a Day of Fun and Philanthropy
    NAPA, Calif., July 27, 2023 /PRNewswire-PRWeb/ -- ZD Wines and the deLeuze Family Charitable Foundation are excited to announce that Crush Challenge , the ultimate food, wine, and cycling lifestyle event in Napa Valley, returns this year on Saturday, August 26, 2023.
  • Proceeds of Crush Challenge are dedicated to finding a non-toxic cure for cancer at UC Davis Comprehensive Cancer Center, as well as providing funding for the Teen Center at Boys & Girls Clubs of Napa Valley.
  • Last year, the event raised a record-breaking $182,500 for the charities, and over $635,000 (net) since inception.
  • Tickets are $250 for the cycling ride, or $25 if you fundraise the rest, and include admission to the Food & Wine Garden.

IO Biotech Provides Business Update

Retrieved on: 
Monday, January 9, 2023

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today provided a business update.

Key Points: 
  • NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® vaccine platform, today provided a business update.
  • “Throughout 2022, the team at IO Biotech made major progress on multiple fronts – advancing our lead program into a global Phase 3 pivotal trial for patients with advanced melanoma, initiating a Phase 2 solid tumor basket study for IO102-IO103 in combination with pembrolizumab, and continuing research on our pipeline assets,” said Mai-Britt Zocca, Ph.D., President and Chief Executive Officer of IO Biotech.
  • We now have four investigator-initiated studies underway in the United States and Europe, with an additional grant being finalized.
  • The company is now supporting four investigator-initiated trials evaluating IO102-IO103 in combination regimens across a variety of cancer types.

SmithGroup Opens Sacramento Office

Retrieved on: 
Wednesday, October 5, 2022

Sacramento, Oct. 05, 2022 (GLOBE NEWSWIRE) -- SmithGroup , one of the nations leading integrated design firms, has opened its latest office in Sacramento .

Key Points: 
  • Sacramento, Oct. 05, 2022 (GLOBE NEWSWIRE) -- SmithGroup , one of the nations leading integrated design firms, has opened its latest office in Sacramento .
  • Arun Kaiwar joined SmithGroup as a principal to lead the local team and day-to-day operations of the office.
  • After partnering with Sacramento clients for decades, we could not be more thrilled to officially open the doors to our new SmithGroup-designed office space right in the heart of the city, said Joyce Polhamus , director of the firms Sacramento, San Francisco and Portland locations.
  • The opening of the Sacramento office is the latest milestone in a pattern of steady growth for SmithGroup, which recently opened locations in Atlanta, Houston and Portland.

Calithera Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Monday, August 15, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended June 30, 2022.
  • Calithera plans to share data from this trial by the first quarter of 2023.
  • Research and development expenses for the second quarter 2022 were $7.8 million, compared to $12.8 million in the same period prior year.
  • General and administrative expenses for the second quarter 2022 were $3.6 million, compared to $4.5 million in the same period prior year.

Calithera Biosciences Shares Progress in Sapanisertib and Mivavotinib Clinical Programs at Upcoming Lung Cancer and Lymphoma Conferences

Retrieved on: 
Wednesday, July 13, 2022

SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, announced that updates related to the ongoing clinical programs for sapanisertib (CB-228) and mivavotinib (CB-659) will be presented at the upcoming International Association for Lung Cancer (IASLC) 2022 World Conference on Lung Cancer (WCLC) and the 2022 Pan Pacific Lymphoma Conference, respectively.

Key Points: 
  • The phase 2 trial ( NCT05319028 ), which enrolled its first patient in June, is an open-label study of mivavotinib monotherapy in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma (DLBCL).
  • Data from this trial could position Calithera to initiate a study with registrational intent in biomarker-specific DLBCL populations.
  • Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations.
  • The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.

Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO™

Retrieved on: 
Wednesday, April 27, 2022

Oncocyte will be distributing a data press release on May 26, 2022, summarizing the results of the posters and the implications for DetermaIO.

Key Points: 
  • Oncocyte will be distributing a data press release on May 26, 2022, summarizing the results of the posters and the implications for DetermaIO.
  • In addition, Oncocyte is supporting a Continuing Medical Education Event (CME) by way of an unrestricted educational grant on June 5, 2022, at 6:30PM CDT.
  • Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer the ASCO Foundation.
  • DetermaIO, a gene expression test currently used as a research-use only tool, assesses the tumor microenvironment to predict response to immunotherapies.

Crush Challenge Is Back in 2021

Retrieved on: 
Tuesday, September 14, 2021

NAPA, Calif., Sept. 14, 2021 /PRNewswire-PRWeb/ -- ZD Wines and the deLeuze Family Charitable Foundation are excited to announce that Crush Challenge , the ultimate food, wine, and cycling lifestyle event in Napa Valley, is back this year on October 9, 2021.

Key Points: 
  • NAPA, Calif., Sept. 14, 2021 /PRNewswire-PRWeb/ -- ZD Wines and the deLeuze Family Charitable Foundation are excited to announce that Crush Challenge , the ultimate food, wine, and cycling lifestyle event in Napa Valley, is back this year on October 9, 2021.
  • Crush Challenge is now in its seventh year, and so far has raised over $325,000 for their nonprofits.
  • Today, Crush Challenge continues to support that research and the UC Davis Health Comprehensive Cancer Center.
  • To join Crush Challenge for the ride, barrel tasting, or the Food & Wine Marketplace, visit http://www.crushchallenge.net .